Free tool
FAERS Monitor: Besremi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761166 or its brand name (Besremi, Ropeginterferon Alfa-2b-Njft). Reports on generic versions are filed under their own applications.
Reports
1,859
Serious
429
23% of reports
Hospitalization
180
Death reported
31
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue355
- off label use304
- pruritus177
- headache157
- product dose omission issue118
- influenza like illness111
- nausea110
- inappropriate schedule of product administration107
- diarrhoea104
- pain104
- arthralgia101
- haematocrit increased93
- platelet count increased91
- dizziness84
- incorrect dose administered77
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 382 |
| 2023 | 774 |
| 2024 | 217 |
| 2025 | 189 |
| 2026 | 292 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,300 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haematocrit increasedSignal | 93 | 481.3 | 393.1 | 42,307 |
| platelet count increasedSignal | 91 | 79.5 | 65.0 | 6,934 |
| influenza like illnessSignal | 111 | 15.3 | 12.8 | 1,471 |
| inappropriate schedule of product administrationSignal | 107 | 6.7 | 5.6 | 519 |
| pruritusSignal | 177 | 5.2 | 4.5 | 609 |
| fatigueSignal | 355 | 5.2 | 4.7 | 1,232 |
| product dose omission issueSignal | 118 | 4.5 | 3.8 | 327 |
| off label useSignal | 304 | 3.9 | 3.5 | 689 |
| incorrect dose administeredSignal | 77 | 3.8 | 3.1 | 159 |
| headacheSignal | 157 | 2.8 | 2.4 | 190 |
| arthralgiaSignal | 101 | 2.7 | 2.3 | 113 |
| pain | 104 | 1.9 | 1.6 | 46 |
| dizziness | 84 | 1.9 | 1.5 | 36 |
| diarrhoea | 104 | 1.8 | 1.5 | 39 |
| nausea | 110 | 1.6 | 1.3 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.